Hans-Joachim Luck
Overview
Explore the profile of Hans-Joachim Luck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401360.
PMID: 39883887
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer...
2.
Mobus V, Luck H, Ladda E, Klare P, Engels K, Schmidt M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):66.
PMID: 39080281
GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n ...
3.
Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kummel S, et al.
Eur J Cancer
. 2024 Jul;
209:114239.
PMID: 39059184
Background: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high...
4.
Hack C, Maass N, Aktas B, Kummel S, Thomssen C, Wolf C, et al.
Geburtshilfe Frauenheilkd
. 2024 May;
84(2):e10.
PMID: 38690326
[This corrects the article DOI: 10.1055/a-2238-3153.].
5.
Hack C, Maass N, Aktas B, Kummel S, Thomssen C, Wolf C, et al.
Geburtshilfe Frauenheilkd
. 2024 Feb;
84(2):185-195.
PMID: 38344045
Introduction: Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with...
6.
Lorusso D, Mouret-Reynier M, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, et al.
Int J Gynecol Cancer
. 2023 Dec;
34(4):550-558.
PMID: 38129136
Objective: In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive...
7.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, et al.
Clin Cancer Res
. 2023 Sep;
29(21):4419-4429.
PMID: 37756555
Purpose: The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing of homologous recombination deficiency (HRD). However, in many countries, access to HRD...
8.
Luck H, Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, et al.
Oncologist
. 2023 Aug;
28(12):e1152-e1159.
PMID: 37555463
Background: Eribulin, a halichondrin-class microtubule dynamics inhibitor, is a preferred treatment option for patients with advanced breast cancer who have been pretreated with an anthracycline and a taxane. Peripheral neuropathy...
9.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al.
J Clin Oncol
. 2022 Nov;
41(4):893-902.
PMID: 36332161
Purpose: To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. Methods: In this multicenter, open-label, randomized...
10.
Reinisch M, Untch M, Mahlberg R, Reimer T, Hitschold T, Marme F, et al.
Breast
. 2022 Oct;
66:110-117.
PMID: 36223695
Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous...